Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021183961 - EXOSOMAL NUCLEIC ACID VACCINE MODULARLY CONFIGURED TO HARNESS MULTIPLE ANTIGEN PRESENTATION MECHANISMS

Publication Number WO/2021/183961
Publication Date 16.09.2021
International Application No. PCT/US2021/022222
International Filing Date 12.03.2021
IPC
C12P 19/34 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/113 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 9/107 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/88 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
88using microencapsulation, e.g. using liposome vesicle
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 2039/55555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
A61K 2039/572
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
572cytotoxic response
A61K 2039/575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
575humoral response
A61K 2039/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
70Multivalent vaccine
A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Applicants
  • THE JOHNS HOPKINS UNIVERSITY [US]/[US]
  • CAPRICOR, INC. [US]/[US]
Inventors
  • GOULD, Stephen John
  • MARBAN, Linda
  • WARSI, Tariq Hussain
Agents
  • HAILE, Lisa A.
Priority Data
62/989,52513.03.2020US
62/990,94617.03.2020US
63/000,21126.03.2020US
63/061,76605.08.2020US
63/108,84702.11.2020US
63/110,32505.11.2020US
63/155,26801.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) EXOSOMAL NUCLEIC ACID VACCINE MODULARLY CONFIGURED TO HARNESS MULTIPLE ANTIGEN PRESENTATION MECHANISMS
(FR) VACCIN À BASE D'ACIDE NUCLÉIQUE EXOSOMAL CONÇU DE FAÇON MODULAIRE POUR EXPLOITER DE MULTIPLES MÉCANISMES DE PRÉSENTATION D'ANTIGÈNES
Abstract
(EN) The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.
(FR) La présente invention concerne des systèmes modulaires pour la vaccination contre des agents infectieux qui impliquent la délivrance, par exemple, d'ARNm codant des antigènes chargés d'exosomes à et dans des cellules et des tissus du sujet immunisé. La présente invention concerne également des compositions et des procédés pour la conception, préparation, fabrication, formulation, et/ou l'utilisation de vaccins, tels que des vaccins à acide nucléique, chargé dans des vésicules extracellulaires, tels que des exosomes chargés avec des ARNm synthétiques codant pour de multiples antigènes de surface et antigènes cytoplasmiques d'intérêt, tels que des polypeptides antigéniques dérivés d'un virus infectieux, tels que le SARS-CoV-2, conçus pour provoquer de fortes réponses immunitaires humorales et cellulaires dues à l'expression simultanée d'antigènes dans leur état natif et en tant qu'antigènes associés à des exosomes.
Latest bibliographic data on file with the International Bureau